Gerty Schreibelt is an immunologist at the department of Tumor Immunology of the Radboud Institute for Molecular Life Sciences. Her research primarily focuses on human natural circulating DC subsets, to understand the functional properties of these dendritic cells and to establish their value for clinical vaccination of cancer. She is highly involved in clinical trials with dendritic cell vaccination of melanoma, prostate cancer and colon carcinoma as well as prophylactic vaccination of Lynch syndrome carriers, to translate findings from preclinical studies into new immunological approaches for treatment of cancer patients. Research interests include antigen uptake, -processing and –presentation by natural dendritic cell subsets and Toll-like receptor mediated dendritic cell maturation, in particular with GMP-grade products for direct application in dendritic cell-based immunotherapy of cancer patients.
Gerty Schreibelt obtained her Masters degree in Biology from the University of Groningen in 2002 and her PhD from the VU University in Amsterdam in 2007. Her thesis focused on the role of reactive oxygen species and oxidative stress in the formation of inflammatory multiple sclerosis lesions. During her PhD, she was a visiting scientist at the Leibniz-Institut für Molekulare Pharmakologie in Berlin, Germany. After obtaining her PhD in 2007, she joined the department of Tumor Immunology in Nijmegen, where she studies the use of dendritic cells as anti-cancer vaccines.Gerty’s research mainly focusses on natural circulating dendritic cell subsets and their application in immunotherapy of cancer. In a recent clinical study, she showed that immunotherapy with naturally circulating dendritic cells can induce potent anti-tumor immune responses and objective clinical responses in advanced melanoma patients. A phase III randomized placebo-controlled trial to prove clinical efficacy of dendritic cell-based immunotherapy is currently ongoing in stage IIIB and IIIC melanoma patients. Gerty is a member of the Dutch-Flemish workgroup on Advanced Therapy Medicinal Products.
Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes.